Information  X 
Enter a valid email address

Qiagen N.V. (0H1Z)

  Print      Mail a friend       Annual reports

Thursday 11 February, 2010

Qiagen N.V.

QIAGEN and Celera Establish Distribution Agreem...

Qiagen N.V. / QIAGEN and Celera Establish Distribution Agreement for Respiratory Pathogen Panel  processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

VENLO, The Netherlands, and ALAMEDA, California -February 11, 2010 - QIAGEN N.V.
(NASDAQ:   QGEN;   Frankfurt   Prime   Standard:  QIA)  and  Celera  Corporation
(NASDAQ:CRA)  today announced an agreement under  which QIAGEN will distribute a
Celera  molecular multiplex assay.  The assay is  the next generation version of
QIAGEN's  ResPlex  II  assay  for  detection of respiratory pathogens. Multiplex
assays  allow testing for a  multiple number of different  pathogens in a single
run. Financial details were not disclosed.

Under  the terms of the agreement, QIAGEN  has the exclusive worldwide rights to
distribute  this multiplex test  kit, which will  be manufactured by Celera. The
new  ResPlex assay  detects 19 different  pathogens associated  with respiratory
infections  and  is  designed  for  use  with  LiquiChip  (Luminex) 100 and 200
instrument platforms.

"Celera's  significant  experience  in  the  development  and  manufacturing  of
molecular  diagnostic products is a very valuable resource and this relationship
can  accelerate our effort  to further expand  our molecular diagnostic solution
portfolio,"  said Peer Schatz, CEO of QIAGEN.  "We believe that this new product
has  the  potential  to  provide  significant value for laboratories, healthcare
professionals and patients worldwide."

"We  are pleased  to have  entered into  this agreement  with QIAGEN  as we look
toward  the  development  and  marketing  of  a molecular diagnostic solution to
address certain infectious respiratory diseases and provide our customers with a
product of the highest quality," said Kathy Ordoñez, CEO of Celera.

The new ResPlex kits will be available through QIAGEN's existing sales channels.
The  new test will be submitted for regulatory approval in the United States and


QIAGEN  N.V., a Netherlands  holding company, is  the leading global provider of
sample  and  assay  technologies.  Sample  technologies  are used to isolate and
process  DNA,  RNA  and  proteins  from  biological  samples  such  as  blood or
tissue. Assay technologies are used to make such isolated bio-molecules visible.
QIAGEN has developed and markets more than 500 sample and assay products as well
as  automated solutions for such  consumables. The company provides its products
to  molecular diagnostics laboratories, academic researchers, pharmaceutical and
biotechnology  companies,  and  applied  testing customers  for purposes such as
forensics,  animal or food testing  and pharmaceutical process control. QIAGEN's
assay  technologies include one  of the broadest  panels of molecular diagnostic
tests  available worldwide.  This panel  includes the  digene HPV Test, which is
regarded  as  a  "gold  standard"  in  testing  for  high-risk  types  of  human
papillomavirus  (HPV), the primary cause of cervical  cancer, as well as a broad
suite  of solutions  for infectious  disease testing  and companion diagnostics.
QIAGEN  employs more than  3,500 people in over  30 locations worldwide. Further
information about QIAGEN can be found at


Statements  contained  in  this  release  that  are  not  historical  facts  are
forward-looking   statements,  including  statements  about  the  new  molecular
multiplex  assay and  our products,  markets and  strategy. Such  statements are
based  on current expectations  that involve risks  and uncertainties including,
but   not   limited   to,  those  associated  with:  management  of  growth  and
international   operations  (including  currency  fluctuations  and  logistics),
variability  of  our  operating  results,  commercial development of our markets
(including  applied testing, clinical and academic research, proteomics, women's
health/HPV testing, molecular diagnostics, personalized healthcare and companion
diagnostics),   our   relationships  with  customers,  suppliers  and  strategic
partners, competition, changes in technology, fluctuations in demand, regulatory
requirements,   identifying,   developing   and  producing  integrated  products
differentiated   from  our  competitors'  products,  market  acceptance  of  our
products,  and integration of acquired  technologies and businesses. For further
information, refer to our filings with the SEC, including our latest Form 20-F.
Information  in this release is as of the  date of the release, and we undertake
no duty to update this information unless required by law.

About Celera:

Celera  is a healthcare business focusing  on the integration of genetic testing
into  routine  clinical  care  through  a  combination  of products and services
incorporating  proprietary  discoveries.  Berkeley  HeartLab,  a  subsidiary  of
Celera,  offers  services  to  predict  cardiovascular  disease risk and improve
patient  management.  Celera  also  commercializes  a  wide  range  of molecular
diagnostic  products throughAbbott  and has  licensed other  relevant diagnostic
technologies  developed to  provide personalized  disease management  in cancer.
Information  about Celera  Corporation, including  reports and other information
filed  by the company with the  Securities and Exchange Commission, is available
at <>.

Celera Forward-Looking Statements

Certain statements in this press release are forward-looking. These may be
identified by the use of forward-looking words or phrases such as "believe,"
"expect," "will," "should," "anticipate," "may," "could," and "intend," among
others. These forward-looking statements are based on Celera's current
expectations. The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for such forward-looking statements. In order to comply with the
terms of the safe harbor, Celera notes that a variety of factors could cause
actual results and experience to differ materially from the anticipated results
or other expectations expressed in such forward-looking statements. The risks
and uncertainties that may affect the operations, performance, development, and
results of our business include, but are not limited to, the risks and
uncertainties that: (1) the agreement with QIAGEN may be terminated; (2) the
risk that the products contemplated by this agreement will not receive
regulatory approvals; and (3) the uncertainty that any products will be accepted
and adopted by the market, including the risk that that these products will not
be competitive with tests offered by other companies. The foregoing list sets
forth some, but not all, of the factors that could affect Celera's ability to
achieve results described in any forward-looking statements. For additional
information about the risks and uncertainties that Celera faces and a discussion
of its financial statements and footnotes, see documents filed by Celera with
the SEC, including its transition report on Form 10-KT and all subsequent
periodic reports. All information in this press release is as of the date of the
release, and Celera does not undertake any duty to update this information,
including any forward-looking statements, unless required by law.

                                     # # #


 Investor Relations:                     Public Relations:
 Dr. Solveigh Mähler                     Dr. Thomas Theuringer
 Director Investor Relations             Associate Director Public Relations
 QIAGEN N.V.                             QIAGEN GmbH
 +49 2103 29 11710                       +49 2103 29 11826
 e-mail:[email protected]      e-mail:[email protected]
 <mailto:[email protected]>    <mailto:[email protected]>

 Albert F. Fleury                        Celera:
 Investor Relations North America        Dr. David Speechly
 QIAGEN N.V.                             +1 510 749-1853
 +1 301 944 7028                         e-mail:[email protected]
 e-mail:[email protected]         <mailto:[email protected]>
 <mailto:[email protected]>


 --- End of Message --- 

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626;ISIN: NL0000240000;Index:Prime All Share,TecDAX,HDAX,MIDCAP;TECH All Share;



a d v e r t i s e m e n t